262 related articles for article (PubMed ID: 37040843)
1. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons.
Le MH; Le DM; Baez TC; Wu Y; Ito T; Lee EY; Lee K; Stave CD; Henry L; Barnett SD; Cheung R; Nguyen MH
J Hepatol; 2023 Aug; 79(2):287-295. PubMed ID: 37040843
[TBL] [Abstract][Full Text] [Related]
2. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
[TBL] [Abstract][Full Text] [Related]
3. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
[TBL] [Abstract][Full Text] [Related]
4. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
Liu J; Ayada I; Zhang X; Wang L; Li Y; Wen T; Ma Z; Bruno MJ; de Knegt RJ; Cao W; Peppelenbosch MP; Ghanbari M; Li Z; Pan Q
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e573-e582. PubMed ID: 33618024
[TBL] [Abstract][Full Text] [Related]
5. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
6. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka.
Niriella MA; Kasturiratne A; Pathmeswaran A; De Silva ST; Perera KR; Subasinghe SKCE; Kodisinghe SK; Piyaratna TACL; Vithiya K; Dassanayaka AS; De Silva AP; Wickramasinghe AR; Takeuchi F; Kato N; de Silva HJ
Hepatol Int; 2019 May; 13(3):314-322. PubMed ID: 30539516
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
Li WD; Fu KF; Li GM; Lian YS; Ren AM; Chen YJ; Xia JR
World J Gastroenterol; 2015 Aug; 21(32):9607-13. PubMed ID: 26327768
[TBL] [Abstract][Full Text] [Related]
8. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis.
Wu Y; Zheng Q; Zou B; Yeo YH; Li X; Li J; Xie X; Feng Y; Stave CD; Zhu Q; Cheung R; Nguyen MH
Hepatol Int; 2020 Mar; 14(2):259-269. PubMed ID: 32130675
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
Chakrabarty M; Jha AN; Sharma DJ
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
[TBL] [Abstract][Full Text] [Related]
10. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.
Wijarnpreecha K; Li F; Lundin SK; Suresh D; Song MW; Tao C; Chen VL; Lok ASF
Aliment Pharmacol Ther; 2023 May; 57(9):1014-1027. PubMed ID: 36815445
[TBL] [Abstract][Full Text] [Related]
11. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study.
Ahmed OT; Gidener T; Mara KC; Larson JJ; Therneau TM; Allen AM
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1374-1381.e6. PubMed ID: 34265444
[TBL] [Abstract][Full Text] [Related]
12. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
[TBL] [Abstract][Full Text] [Related]
13. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus.
Chen N; Zhou J; Wang K; Li X; Li Z
BMJ Open Diabetes Res Care; 2023 Feb; 11(1):. PubMed ID: 36792168
[TBL] [Abstract][Full Text] [Related]
14. Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study.
Li Y; Zheng R; Li J; Feng S; Wang L; Huang Z
Lipids Health Dis; 2020 Oct; 19(1):229. PubMed ID: 33109219
[TBL] [Abstract][Full Text] [Related]
15. Association of non-alcoholic fatty liver disease with total testosterone in non-overweight/obese men with type 2 diabetes mellitus.
Yang LJ; Zhou JZ; Zheng YF; Hu X; He ZY; Du LJ; Gu X; Huang XY; Li J; Li YQ; Pan LY; Zhang XX; Gu XJ
J Endocrinol Invest; 2023 Aug; 46(8):1565-1572. PubMed ID: 36725809
[TBL] [Abstract][Full Text] [Related]
16. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis.
Tang A; Ng CH; Phang PH; Chan KE; Chin YH; Fu CE; Zeng RW; Xiao J; Tan DJH; Quek J; Lim WH; Mak LY; Wang JW; Chew NWS; Syn N; Huang DQ; Siddiqui MS; Sanyal A; Muthiah M; Noureddin M
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1750-1760.e12. PubMed ID: 35863685
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of cardiometabolic disease in normal-weight individuals with non-alcoholic fatty liver disease.
Seo MW; Eum Y; Jung HC
Obes Res Clin Pract; 2023; 17(5):390-397. PubMed ID: 37775401
[TBL] [Abstract][Full Text] [Related]
18. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
Friedrich D; Marschall HU; Lammert F
BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
[TBL] [Abstract][Full Text] [Related]
19. Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.
Liu J; Tian Y; Fu X; Mu C; Yao M; Ni Y; Liu Y; Li Z
Chin Med J (Engl); 2022 Jul; 135(14):1682-1691. PubMed ID: 36070463
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
